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A
mAbstract
Background: The renin-angiotensin system (RAS) plays a role in the pathogenesis of
ARDS, Angiotensin II (Ang-II) contributing to the pathogenesis of inflammation and
fibrogenesis. Angiotensin-(1-7) (Ang-(1-7)) may antagonize the effects of Ang-II. This
study was aimed at evaluating the potential for Ang-(1-7) to reduce injury,
inflammation and fibrosis in an experimental model of ARDS in the acute and late
phases.
Methods: Male Sprague Dawley rats underwent an instillation of 0.1 M hydrochloric
acid (HCl, 2.5 ml/kg) into the right bronchus. In an acute ARDS study, acid-injured rats
were subjected to high stretch mechanical ventilation (18 ml/kg) for 5 h and
randomized to receive an intravenous infusion of either vehicle (saline), Ang-(1-7) at low
dose(0.27 μg/kg/h) (ALD), or high dose (60 μg/kg/h) (AHD) starting simultaneously with
injury or 2 h afterwards. Arterial blood gas analysis and bronchoalveolar lavage (BAL)
were performed to assess the injury. For the late ARDS study, after HCl instillation rats
were randomized to either vehicle or high dose Ang-(1-7) (300 μg/kg/day) infused by
mini osmotic pumps for two weeks, and lung hydroxyproline content measured.
Results: In the acute ARDS study, Ang-(1-7) led to a significant improvement in
oxygenation (PaO2/FiO2 : vehicle 359 ± 86; ALD 436 ± 72; AHD 44 442 ± 56; ANOVA
p = 0.007) and reduced white blood cells counts (vehicle 4,519 ± 2,234; ALD
2,496 ± 621; AHD 2,744 ± 119/mm3; ANOVA p = 0.004). Only treatment with high dose
Ang-(1-7) reduced inflammatory cell numbers in BAL (vehicle 127 ± 34; AHD
96 ± 34/ μl; p = 0.033). Interestingly also delayed administration of Ang-(1-7) was
effective in reducing injury. In later ARDS, Ang-(1-7) decreased hydroxyproline content
(649 ± 202 and 1,117 ± 297 μg/lung; p < 0.05).
Conclusions: Angiotensin-(1-7), decreased the severity of acute lung injury and
inflammation induced by combined acid aspiration and high stretch ventilation.
Furthermore, continuous infusion of Ang-(1-7) reduced lung fibrosis 2 weeks following
acid aspiration injury. These results call for further research on Ang-(1-7) as possible
therapy for ARDS.
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To date, no therapies are available to modify the clinical course and improve the
outcome of Acute Respiratory Distress Syndrome (ARDS) [1]. The only supportive
strategies are mechanical ventilation and conservative management of intravenous
fluids, but prolonged ventilation could exacerbate a pre-existing lung injury and lead to
ventilator-induced lung injury (VILI) [2].
The pathogenesis of ARDS can be influenced by the activation of the renin-
angiotensin system (RAS), a well-known hormonal system involved in the regulation of
blood pressure homeostasis and fluid and salt balance. The main effector of this system
is angiotensin II (Ang-II), which derives from the proteolytic cleavage of angiotensin I
(Ang-I) by angiotensin converting enzyme (ACE). Ang-II, in addition to its hemodynamic
functions, is involved in inflammatory and fibrogenic processes [3-5]. Indeed the activa-
tion of Ang-II and its receptor angiotensin II receptor type 1 (AT1R) plays a role in the
pathophysiology of several diseases, including atherosclerosis, myocardial infarction,
stroke, diabetes, nephrosclerosis, and tumorigenesis [5]. An association has been demon-
strated between ACE polymorphism and the susceptibility, progression and outcome in
ARDS [6-9].
In parallel with ACE/Ang-II/AT1R axis, renin-angiotensin system has a counter-
regulatory axis, which is composed by angiotensin-(1-7) (Ang-(1-7)), its receptor Mas,
and the main rate limiting step ACE2 [10]. Ang-(1-7) is a biologically active heptapeptide
released from the cleavage of Ang-II by ACE homolog ACE2 or from Ang-I by other pep-
tidases [11-13]. It exerts its action via the Mas receptor, which is a non-AT1/AT2 G
protein-coupled receptor. Ang-(1-7) mediates some ACE inhibitor-related effects: it op-
poses Ang-II actions, especially vasoconstriction [14], proliferation [15], and inflammation
[16]. In a model of antigen-induced arthritis [17], Ang-(1-7) modulated rolling and adhe-
sion of leukocytes to endothelium with improvement of joint hypernociception. Ang-(1-7)
can inhibit leukocyte pro-inflammatory functions by activating Mas receptor on their sur-
face [5]. In the context of ARDS, Imai et al. showed the crucial involvement of ACE2 in
the pathogenesis of ARDS in three different experimental models [18]. In particular,
ACE2 knockout mice showed greater lung elastance than control mice, worst oxygen-
ation, and increased inflammation in experimental models of acute lung injury induced by
acid aspiration or endotoxin (LPS) or caecal ligation and puncture (CLP) [18]. Moreover
the administration of recombinant human ACE2 in wild-type mice attenuated acute lung
injury, demonstrating the protective effects of ACE2 [18]. Other studies demonstrated
that Ang-(1-7) acts also on lung remodeling and fibrosis development, Ang-(1-7) can en-
hance the apoptosis of fibrocytes, and reduces the expression of transforming growth fac-
tor β (TGF-β) and collagen deposition [16,19-22]. In a bleomycin-induced lung fibrosis
model, the intratracheal administration of Ang-(1-7) through lentivirus led to a significant
reduction in pulmonary fibrosis [23]. The potential for Ang-(1-7) to attenuate ARDS se-
verity and lung fibrosis in preclinical ARDS models is not known.
Even if the beneficial effects of Ang-(1-7) in different models of ARDS have already
been shown [24], we aimed to further exploit the therapeutic potential of Ang-(1-7) for
ARDS, also administrating it with a delayed timing in the acute phase and for a pro-
longed period of 2 weeks to evaluate the impact of fibrosis. To the best of our know-
ledge, these aspects have not been addressed in previous studies. We hypothesized that,
in early ARDS, Ang-(1-7) would reduce the severity of lung injury induced following
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ical ventilation.
Prolonged ARDS requiring ongoing mechanical ventilation can induce lung fibrosis,
which is a significant contributor to poor outcome in ARDS [25]. Given this, we further
wished to determine the potential for Ang-(1-7) to attenuate the development of
fibrosis in an experimental model of late ARDS induced by unilateral acid instillation
[26]. We hypothesized that continuous Ang-(1-7) treatment could reduce the collagen
deposition and improve long-term outcome.
Methods
Animals
Male Sprague Dawley rats (200 to 250 g) were obtained from Harlan Laboratories
(Udine, Italy) and maintained under standard laboratory condition in Bicocca University
in Monza (Italy). Procedures involving animals and their care were conducted in conform-
ity with the institutional guidelines complying with national (D.L. n. 116, G.U., suppl. 40,
18 Febbraio 1992, Circolare n. 8, G.U., 14 Luglio 1994) and international laws and policies
(EEC Council Directive 86/609, OJ L 358, 1, 12 December 1987; US National Research
Council’s Guide for the Care and Use of Laboratory Animals, 2011). The study was ap-
proved by the ethical committee of our institution.
Acute ARDS study: two-hit model
Animals were anesthetized with Ketamine 100 mg/kg and Xylazine 4 mg/kg (Ketavet
100, Intervet Productions, Aprilia, Latina, Italy; Rompun 2%, Bayer, Milano, Italy), oro-
tracheally intubated and subjected to high stretch ventilation (Inspira ASV, Harvard
Apparatus, Holliston, MA, USA) with the following parameters: tidal volume 18 ml/kg;
respiratory rate 35/min; PEEP 2 to 2.5 cmH2O; inspiration to expiration ratio (I/E)
35%; fraction of inspired oxygen (FiO2) 0.5. At the beginning, after 3 h of treatment
and at the end of the 5-h experiment, a recruitment maneuver (to 30 cmH2O for 10 s)
was performed. Injury was induced by instillation of 0.1 M hydrochloric acid (HCl)
(2.5 ml/kg) into the right bronchus through a PE10 catheter. Acid-induced damage in
the right lung was confirmed by micro-computed tomography (see the ‘Assessment of
injury’ section). When we identified that HCl instillation involved the contralateral
lung, the animals were euthanized and excluded from analysis (approximately 2%).
Anesthesia and paralysis were maintained throughout the experiment by infusion in the
right carotid of Propofol 13 mg/kg/h and Ketamine 5 mg/kg/h and in the right jugular
of Rocuronium bromide (Rocuronio, Fresenius Kabi Italia, Isola della Scala, Verona,
Italy) 1.5 mg/kg/h and Ringer acetate 1.8 ml/h. A group of rats (n = 5), that received an
instillation of 2.5 ml/kg of sterile saline (NaCl 0.9%) and underwent prolonged mechan-
ical ventilation with same ventilation settings, was used as control group (CTRL). A
group of healthy rats (n = 6) did not undergo any of the surgical interventions and was
sacrificed (Healthy rats).
Series 1 - early therapy with Ang-(1-7)
Immediately after acid instillation, rats were randomized to receive intravenous treatment
(left jugular vein) depending on the randomly assigned experimental group (infusion rate
200 μl/kg/h):
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– Ang-(1-7) low dose (ALD): rats treated with Ang-(1-7) at a dosage of 0.27 μg/kg/h
– Ang-(1-7) high dose (AHD): rats treated with Ang-(1-7) at a dosage of 60 μg/kg/hSeries 2 - rescue therapy with Ang-(1-7)
In this series, rats underwent high stretch ventilation and acid instillation as described
above. Two hours after HCl instillation, animals were randomized to ‘rescue’ treatment
with as follows:
– Vehicle: rats treated with vehicle (NaCl 0.9%)
– Ang-(1-7) high dose: rats treated with Ang-(1-7) at a dosage of 100 μg/kg/h
In this series the total dose of Ang-(1-7) was the same as the AHD group in series 1.Hemodynamic monitoring
In both series, invasive arterial, central venous, and airway pressures were monitored
using pressure transducers, which were interfaced to a PowerLab (AD Instruments,
Colorado Springs, CO, USA) signal transduction unit.Assessment of injury (after 5 h of treatment in series 1 and 2)
Blood withdrawal: blood samples were collected at different time points: immediately before
the treatment (start), after 3 h and at the end of the 5-h experiment (end), and they were
collected from the right carotid artery to perform peripheral leukocyte (WBCs) counts.
Arterial blood gas analysis: at the same time points, gas exchange was assessed by
measuring arterial pressure of oxygen (PaO2), arterial pressure of carbon dioxide
(PaCO2), pH, and base excess (BE) with i-STAT portable analyzer (Oxford Instruments
S.M., Burke and Burke, Menfis Biomedica, Milan, Italy).
Computed tomography (CT) scan: animals underwent two CT scans (Skyscan 1176,
Bruker, Brussels, Belgium). The first scan was performed immediately after the acid in-
stillation in order to verify the extent of injury and the selective instillation of acid into
the right lung, with these parameters: exposure 65 ms, voltage 80 kV, current 300 μA,
and resolution 35 μm (scanning duration about 5 min). At the end of the experiment,
the second scan was performed in order to measure the amount of hypoaerated areas
of parenchyma in the left and right lung separately. This scanning (taking about
20 min) was gated on respiratory cycles.
Respiratory system compliance: respiratory system static compliance was measured
every hour during mechanical ventilation by end-inspiratory occlusions and calculated
according to standard formulas.
Broncho-alveolar lavage (BAL): rats were euthanized (via exsanguination), and BAL
was performed in right and left lung separately. Total protein content and total and
differential cell counts were analyzed, and BAL fluid were stored for inflammatory
cytokines (interleukin-1β (IL-1β), interleukin-6 (IL-6), keratinocyte-derived cytokine
(KC), macrophage inflammatory protein-1α (MIP-1α)) dosage by luminex kit (Milliplex®
Map Kit, Millipore S.p.A., Vimodrone, Italy), according to manufacturer’s instructions.
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pathologist (VC). Briefly, the lungs were excised, were fixed in 4% formaldehyde for
24 h (at a pressure of 20 cmH2O for the first 30 min), and then paraffin embedded and
sectioned. Transverse sections (5 μm) were obtained by cutting the lungs from apex to
base and then stained with hematoxylin and eosin (Sigma-Aldrich, St. Louis, MO,
USA). Histopathologic examination was performed according to our previous study
[25], evaluating the following six pathologic findings: alveolar serofibrinous exudate
with hyaline membranes formation, alveolar hemorrhage, alveolar inflammatory cells,
alveolar septa thickening, parenchymal necrosis, and fibrosis. Severity and extension of
each pathologic finding were scored for severity as 0 (absent), 1 (mild), 2 (moderate),
and 3 (marked) and for extension as 0 (absent), 1 (>0% and ≤25%), 2 (>25% and ≤50%),
and 3 (>50%). A mean score for each finding for each lung was derived and expressed
as the product of extent and severity.
Late ARDS study: unilateral acid aspiration model
Rats were anesthetized with Ketamine 100 mg/kg and Xilazine 4 mg/kg, orotracheally
intubated and ventilated (Inspira ASV, Harvard Apparatus, Holliston, MA, USA) with
the same parameters used above. 0.1 M HCl (2.5 ml/kg) was instilled into the right
bronchus through a PE10 catheter. The mechanical ventilation continued for 15 min
and rats were maintained in the reverse-Trendelenburg position. Animals were extu-
bated and kept in an oxygenated (FiO2 0.5) chamber until full awakening. Rats were
housed three/cage for 2 weeks in Specific Pathogen Free conditions, until sacrifice. A
group of healthy rats (n = 6) did not undergo any of the surgical interventions and was
sacrificed (Healthy rats).
Treatment protocol
Administration of Ang-(1-7) or vehicle (NaCl 0.9%) started 10 min after the HCl
instillation through the use of Alzet mini-osmotic pumps (Model 2002, DURECT
Corporation, Cupertino, CA, USA), which were implanted and tunneled subcutane-
ously, with a mean pumping rate of 0.44 μl/h for 2 weeks until the rats were sacri-
ficed. Throughout the study period, dosages were maintained as specified above. In
this part of the study, we studied only on the dose (300 μg/kg/day) of Ang-(1-7), that
demonstrated beneficial effects in the acute phase (see the ‘Results’ section). Ten rats
were excluded from analysis (n = 7 vehicle, n = 3 Ang1-7) because of an evident in-
flammatory reaction localized near the subcutaneous mini-osmotic pump, which
casts some doubts on the actual drug delivery and represents an additional source of
inflammation.
Assessment of injury
Blood oxygen saturation (SpO2): 1 week after the HCl instillation, the arterial
hemoglobin saturation was measured through an animal oximeter pod (red and infrared
light passed through pulsating blood in vascular tissue) placed on the hind leg (Animal
Oximeter Pod, ML325, ADInstruments, Colorado Springs, CO, USA).
Respiratory system compliance: After 2 weeks of treatment in anesthetized rats,
respiratory system compliance was measured through the construction of a PV curve:
after a recruitment maneuver (to 30 cmH2O for 10 s), five steps of inspiratory volumes
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12.5 ml. For each step, the plateau pressure was recorded in order to calculate the static
compliance.
CT scan: rats underwent two micro-CT scans (eXplore Locus, GE Healthcare, Pewaukee,
WI, USA): 24 h after injury and at the end of the experiment. The CT parameters were as
follows: voltage 80 kV, current 450 μA, and resolution 93 μm. The scans were acquired
over 10 min. Images were analyzed to measure the amount of hypoaerated areas of paren-
chyma in the left and right lung separately.
Collagen content in pulmonary tissue: after animal’s euthanasia, lungs were excised and
stored at −80°C. The collagen content was measured indirectly with the OH-proline assay.
We used the conventional method, which entails lung tissue homogenization and hydrolysis
with 6 N HCl at 120°C, chloramine T and Ehrlich’s solution were added to samples for the
OH-proline oxidation and a colorimetric reaction. Absorbance was measured at 550 nm.Exclusion criteria
Animals were excluded from the protocol on fulfillment of two predefined criteria,
namely: (1) evidence on CT of lung injury to the left lung following acid instillation
(i.e., model failure); or (2) malfunctioning of the injection pumps (i.e., non-delivery
of Ang(1-7)). In the case of animal death, this precluded further physiologic data col-
lection, but animal survival data was included in the analysis.Statistical analysis
All data presented in this report are expressed as mean ± standard deviation. For the acute
ARDS, study treatments with Ang-(1-7) at two doses and vehicle were compared by means
of one way ANOVA analysis and followed by Tukey post hoc test. For the comparison be-
tween vehicle group and CTRL group, and between the two rescue treatment groups, t-test
analysis was used. For the study of the late phase, angiotensin 1-7 was compared with ve-
hicle by t-test analysis. A level of p < 0.05 was considered as statistically significant.Results
Acute ARDS study. Two-hit model
Series 1 - early therapy with Ang-(1-7)
Angiotensin-(1-7) effects on pulmonary pathophysiology We did not find any differ-
ence between groups in terms of hemodynamics and airway pressures during the
experiment, as shown in Table 1.
Arterial oxygenation was similar in all groups immediately after acid instillation. At
the end of the experiment, vehicle-treated rats showed a significant reduction in oxy-
genation compared to CTRL rats (554 ± 9 mmHg, p = 0.001). Ang-(1-7) treatment at
both doses significantly attenuated the decrement in arterial oxygenation induced by
acid instillation (Figure 1A) compared to vehicle treatment. Different treatments did
not result in differences in terms of levels of carbon dioxide, pH, and BE.
As expected, lung compliance in vehicle group was significantly reduced if compared
to CTRL rats (0.44 ± 0.03; p = 0.014). All groups immediately after acid instillation
showed similar respiratory system compliance, and Ang-(1-7) treatment seemed not to
Table 1 Hemodynamics and airway pressure
Experimental groups (n) Part (mmHg) CVP (mmHg) Paw (cmH2O) Ppeak (cmH2O) PEEP (cmH2O)
Vehicle (15) 112 ± 20 3.2 ± 0.9 5.7 ± 0.5 19.7 ± 2.0 2.3 ± 0.2
ALD (11) 117 ± 16 3.0 ± 0.8 6.0 ± 0.7 21.5 ± 3.5 2.2 ± 0.2
AHD (13) 123 ± 16 3.4 ± 0.8 5.8 ± 0.4 19.7 ± 1.5 2.4 ± 0.2
Part, arterial pressure; CVP, central venous pressure; Paw, mean airway pressure; Ppeak, peak of airway pressure; PEEP,
positive end-expiratory pressure. Results are expressed as mean ± SD.
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(Figure 2) measured at the end of experiment (5 h).
Rats that received saline instillation instead of acid showed a significant lower alter-
ation (p = 0.019) of permeability than vehicle group in the right lung: total protein con-
tent was 722 ± 42 μg/ml in right and 692 ± 29 μg/ml in left lung. Ang-(1-7) treatment
did not modify the alteration of alveolar permeability, as the total protein content was
very similar in all groups, as shown in Table 2.
Angiotensin-(1-7) effects on inflammation As index of the systemic inflammation,
peripheral white blood cell counts were performed: cellular counts were similar in all
groups immediately after injury (vehicle: 8,271 ± 3,054; ALD: 8,681 ± 2,919; AHD: 9,085Figure 1 Partial pressure of oxygen and fraction of inspired oxygen ratio (PaO2/FiO2) measured
at the end of the protocol. (A) Series 1 - Early therapy: ANOVA effect of treatment at the end p = 0.007;
*p = 0.030 and #p = 0.013 vs vehicle. Vehicle n = 14; ALD n = 11; AHD n = 13. (B) Series 2 - Rescue therapy:
§p = 0.043 vs vehicle. Vehicle n = 5; Ang-(1-7) n = 5. Healthy rats (dotted line). Results are expressed
as mean ± SD.
Figure 2 Final respiratory system compliance in vehicle and Ang-(1-7) (ANOVA p = n.s.) treated groups.
Vehicle n = 20; ALD n = 12; AHD n = 14. Healthy rats = 0.65 ml/cmH2O. Results are expressed as mean ± SD.
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1,622/mm3), but after 5 h of treatment with Ang-(1-7) at both doses, the number was sig-
nificantly reduced, compared to vehicle treatment (Figure 3). As a measure of the alveolar
inflammatory response, we evaluated the alveolar cell recruitment and the cytokine levels.
Ang-(1-7) treatment reduced the number of inflammatory cells recruited in BAL. In par-
ticular, the high dose treatment led to a lesser number of total cells in BAL in both lungs,
whereas the low dose affected only the left lung (not directly injured by acid) (Figure 4A).
Rats in CTRL group had significantly lower (p = 0.045) polymorphonuclear (PMN)
count in BAL in the right lung (right lung: 15 ± 5/μl, left lung: 6 ± 3/μl) when com-
pared to the vehicle treatment. While the number of PMN in BAL seemed to be not
reduced in AHD group compared to the vehicle (Figure 4C).
We did not find any effect of Ang-(1-7) on cytokine BAL levels, as shown in Table 3.
Histology and imaging Major histopathological findings are summarized in Table 2
and Figure 5. A trend towards reduced alveolar inflammatory infiltrates, parenchymal
necrosis and serofibrinous exudate, although not reaching statistical significance was notedTable 2 BAL total protein concentration and histological analysis in vehicle and
Ang-(1-7) treated groups
Alveolar permeability and histology Lung Vehicle ALD AHD
Permeability: BAL total protein content
Protein content (μg/ml) Right 2,454 ± 1,142 2,600 ± 844 2,536 ± 710
Left 1,108 ± 668 1,406 ± 808 1,213 ± 610
Histological analysis
Alveolar serofibrinous exudate Right 1.4 ± 0.5 2.0 ± 2.7 1.2 ± 0.9
Left 1.0 ± 1.0 1.0 ± 1.0 0.3 ± 0.6
Alveolar hemorrhages Right 0.7 ± 0.9 0.7 ± 1.1 0.7 ± 1.7
Left 0 ± 0 0 ± 0 0 ± 0
Alveolar inflammatory cells Right 0.8 ± 0.8 0.4 ± 1.2 0.5 ± 0.8
Left 0 ± 0 0 ± 0 0 ± 0
Parenchymal necrosis Right 1.6 ± 3.1 1.2 ± 2.3 1.2 ± 2.6
Left 0.3 ± 0.6 0 ± 0 0 ± 0
Results are expressed as mean ± SD.
Figure 3 Peripheral white blood cells counts at the end of experiment (after 5 h). ANOVA, effect of
treatment p = 0.004. *p = 0.006 and #p = 0.025 vs vehicle. Vehicle n = 15; ALD n = 12; AHD n = 10. Results are
expressed as mean ± SD.
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groups.
No differences were found in terms of percentage of hypoaerated areas between
groups, neither immediately after HCl instillation nor at the end of experiment
(Figure 6).Figure 4 Total cells recruited in alveolar spaces. (A) Series 1 - Early therapy: in right (ANOVA p = 0.035)
and left (ANOVA p = 0.004) lung. *p = 0.033 vs vehicle, #p = 0.006 vs vehicle and °p = 0.034 vs vehicle in the
same lung. (B) Series 2 - Rescue therapy. Vehicle n = 5; Ang-(1-7) n = 5. Total PMN recruited in alveoli. (C)
Series 1 - Early therapy: in right (ANOVA p = n.s) and left (ANOVA p = n.s). Vehicle n = 16; ALD n = 11; AHD
n = 11. (D) Series 2 - Rescue therapy: §p = 0.021 vs vehicle. Vehicle n = 5; Ang-(1-7) n = 5. Healthy rats (dotted
line). Results are expressed as mean ± SD.
Table 3 BAL cytokines dosage (pg/ml) in vehicle and Ang-(1-7) treated groups
Experimental
groups (n)
IL-1β (pg/ml) IL-6 (pg/ml) KC (pg/ml) MIP-1α (pg/ml)
Right Left Right Left Right Left Right Left
Vehicle (14) 68 ± 32 40 ± 29 3,423 ± 1,460 1,697 ± 2,112 2,133 ± 608 1,337 ± 895 45 ± 35 20 ± 15
ALD (10) 91 ± 47 68 ± 57 3,771 ± 1,647 1,958 ± 2,964 3,003 ± 1,257 1,900 ± 1,472 67 ± 39 22 ± 16
AHD (9) 83 ± 23 38 ± 28 4,465 ± 1,972 1,300 ± 554 2,809 ± 1,198 2,366 ± 999 54 ± 22 22 ± 16
Healthy rats (6) 27 ± 10 15 ± 6 253 ± 220 357 ± 78 233 ± 106 104 ± 43 15 ± 10 10 ± 8
Results are expressed as mean ± SD. (ANOVA p = n.s.).
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In series 2, Ang-(1-7) was effective in improving oxygenation and also if administrated
as rescue treatment 2 h after the injury (p = 0.043), as shown in Figure 1B. Moreover,
the rescue treatment with Ang-(1-7) induced a significant decrease (p = 0.021) in alveo-
lar PMN in the right lung if compared to vehicle treatment, while no difference was
detected in the left lung (Figure 4D). We also observed the effect of Ang-(1-7) on diuresis:
the urine volume increased significantly if compared to vehicle group (vehicle:
2.9 ± 0.6 ml/5 h, Ang-(1-7): 7.9 ± 4.2 ml/5 h; p = 0.030)), which was not significant
in series 1 (data not shown).Late ARDS study. Unilateral acid aspiration model
Angiotensin-(1-7) effects on lung fibrotic evolution
One week after acid instillation, blood oxygen saturation was significantly higher in
Ang-(1-7) group compared to that in the vehicle group, as shown in Figure 7. Albeit
the difference was minimal, it reinforces the finding of an improved oxygenation re-
ported in the acute phase.
The lung mechanical properties measured at the end of experiment were not differ-
ent between two groups: vehicle 0.65 ± 0.14 and Ang-(1-7) 0.62 ± 0.06 ml/cmH2O.
Healthy rats showed a respiratory system compliance of 0.73 ± 0.04 ml/cmH2O.
At the end of experiment, right lungs from rats treated with angiotensin-(1-7)
showed a significant reduction in collagen deposition, indirectly measured through
OH-proline assay (Figure 8).Discussion
The RAS plays an important role in the pathogenesis of ARDS; in particular, it can be
considered as an important element in the inflammatory response, since angiotensin II
acts as a growth factor regulating cell growth and fibrosis [3]. The ACE2/Ang-(1-7) axis
exerts protective effects in several pathological scenarios in different organs, by opposing
the overactivation of ACE/Ang-II axis [19]. The aim of this study was to test the efficacy
of angiotensin-(1-7) administration as treatment of ARDS in the two phases of the
disease, the acute and the late in an experimental model of acid-induced lung injury.
To this end, we used our recently published two-hit model of acute lung injury [27]
induced by unilateral acid instillation and prolonged injurious ventilation in these stud-
ies. A key feature of this model is the presence of a lung (the right one) subjected to a
double insult (acid aspiration and injurious mechanical ventilation) and the other lung
(left) that only receives injurious mechanical ventilation. This model is a valid model of
Figure 5 Major histopathological findings. (A) Vehicle. Within the lumina of alveoli, there are mats of
pale eosinophilic finely beaded to fibrillar material (fibrin), in which are embedded moderate numbers of
both viable and degenerated (karyorrhectic) neutrophils. (B) ALD. No inflammatory cells detectable within
alveolar lumina. (C) AHD. Note within the lumina of slightly compressed alveoli scattered neutrophils (right
lung, hematoxylin-eosin, 200×, scale bar = 100 μm).
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logical evidence of tissue injury, alteration in the alveolar capillary barrier, presence of
inflammatory response, and evidence of physiological dysfunction. It is known that high
tidal volume ventilation causes VILI after acid instillation in rats [29]: however, to show
that this model was more injurious than prolonged mechanical ventilation alone, rats
treated with sterile saline instead of hydrochloric acid and mechanically ventilated for
Figure 6 Percentage of hypoaerated areas and representative CT images. (A) Percentage of
hypoaerated areas of parenchyma measured on CT image obtained immediately after HCl instillation and at
the end of experiment. Vehicle n = 9; ALD n = 7; AHD n = 6. (B) Representative CT images at the apical and
basal level in Healthy rats, vehicle, ALD and AHD groups. Regions of interest for hypoaeration measurement
in right lung are outlined.
Figure 7 Arterial hemoglobin saturation in vehicle an Ang1-7 group. *p = 0.032 vs Ang1-7. Vehicle
n = 7; Ang-(1-7) n = 8. Healthy rats (dotted line). Results are expressed as mean ± SD.
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Figure 8 OH-Proline content in vehicle and Ang1-7 group. OH-Proline content in right and left lung
shown separately, *p = 0.006 vs Ang1-7 right lung. Vehicle n = 7; Ang-(1-7) n = 8. Healthy rats: right lung
(solid black line) and left lung (dotted black line). Results are expressed as mean ± SD.
Zambelli et al. Intensive Care Medicine Experimental  (2015) 3:8 Page 13 of 175 h were used as control. Our results demonstrated that the two-hit model showed a
significant alteration of pulmonary function (gas exchange and respiratory system com-
pliance), increase in PMN alveolar recruitment as index of inflammatory response, and
alteration of alveolar capillary barrier. This model resembles to some extent the in-
homogeneity of ARDS in the clinical setting. Indeed in the same subject, it’s possible to
study an area injured by acid instillation and mechanical ventilation (right lung) and at
the same time a region injured by mechanical ventilation only (left lung).
Ang-(1-7) administration proved to be safe and well tolerated in our experimental
setting: only a slight and transient (10 to 15 min) decrease in systemic blood pressure
was detected in the acute phase study, confirming the vasodilator effect of Ang-(1-7)
which has been shown to be mediated through the production of endothelial nitric
oxide [30]. We found no difference in survival in both ARDS studies: almost 80% of
animals in all groups survived until the end of experiments.
The main findings obtained in the study are the beneficial effects of Ang-(1-7) on the
oxygenation, inflammatory cells infiltrates, and fibrosis. The Ang-(1-7) treatment atten-
uated the decrease in gas exchange in rats subjected to acid instillation and 5 h of
injurious mechanical ventilation: rats treated with Ang-(1-7) showed better partial
pressure of oxygen compared to rats treated with vehicle only (an increase of 22%).
Interestingly, this finding was confirmed in the late ARDS model, 1 week after the
acid instillation, as demonstrated by the measurement of blood oxygen saturation. It
should be stressed that while this improvement (99.4% vs 98.5%) is certainly not clin-
ically relevant, mostly because of the limited degree of hypoxia in this long-term
model, at the same time, it supports the positive data obtained in the acute phase
study. However, the lung function improvement did not seem to reflect on pulmon-
ary mechanical properties. In fact, no improvement in respiratory system static com-
pliance was detected in Ang-(1-7) higher dose group in acute phase study.
Inflammatory cell migration was significantly reduced in Ang-(1-7) groups: both
numbers of white blood cells and total BAL cells (Figures 3 and 4A) are significantly
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count (Figure 4B). A reduced systemic spread of the local inflammatory stimulus could
also explain the decreased peripheral white blood cells; at the same time, Ang(1-7) is
known to have direct effects on erythropoiesis [31], although this mechanism is less
likely due to the limited time of observation. Moreover, histological analysis showed a
reduced although not statistically significant presence of alveolar inflammatory cells
(Table 2). Overall, these results confirm Ang-(1-7)-mediated inhibition of leukocyte
migration in different pathologies, such as acute renal injury [32], antigen-induced arth-
ritis [17], and cardiomyopathy [21]. Moreover, a very recent study performed by Klein
and coworkers [24] demonstrated how Ang-(1-7) protects from three experimental
lung injury: oleic acid, acid aspiration, and mechanical ventilation. It clearly attenuated
alveolo-capillary barrier failure, neutrophil influx into the lung, and histological evi-
dence of lung injury. In contrast to our results on inflammatory cell lung influx, we
failed to find any difference in BAL levels of different cytokines (IL-1β, IL-6, KC, and
MIP-1α). In fact, it seemed that Ang-(1-7) treatment did not affect cytokine produc-
tion. These results are in line with those obtained by Arndt et al. in 2006 [33], that
showed that the diminution in neutrophil recruitment in lung was not dependent on a
decrease in neutrophil chemoattractants (i.e,. KC and MIP-2) in the setting of systemic
ACE inhibition in lypopolysaccharide-induced lung injury in mice. A possible hypoth-
esis that can be drawn to explain this finding is the involvement of nitric oxide (NO).
Ang-(1-7) can induce the activation of endothelial NO synthase (eNOS) [34] and the
bradykinin-mediated NO-release [35]. NO, besides its vasodilatory and anti-aggregant
functions, inhibits neutrophil recruitment, by acting on neutrophil movement in
vascular bed and on the neutrophil-endothelial interactions, via the suppression of
adhesion molecules [36]. Although Klein et al. [24] found a significant protective
effect of Ang-(1-7) on alveolo-capillary barrier, the total BAL protein content in our
experimental setting was not different between the analyzed groups. One of the reasons
for the lack of the effect on protein extravasation, in our study, could be related to the ex-
perimental model: the caustic action of acid direct on a limited area (right lung) and the
following prolonged mechanical ventilation may cause such an intense fluid extravasation
into the alveolar space that the 5-h time period could not be sufficient for the treatment
to exert its entire effect.
The therapeutic potential of Ang-(1-7) treatment was underlined in a separate set of
experiments (series 2), where ‘rescue therapy’ starting 2 h after HCl instillation demon-
strated a significant improvement of arterial oxygenation and inflammatory response
(in terms of PMN recruitment into alveoli). This is probably one of the major elements
of novelty of this paper, when compared to the paper by Klein [24], in adjunct to the
evaluation on the long-term development of fibrosis and the use of a two-hit model.
Interestingly in this experiment, we found a role of Ang-(1-7) on diuresis: it seemed
that a higher infusion rate of Ang-(1-7) (100 μg/kg/h) induced an increase in urine
volume if compared to vehicle treatment, confirming data in literature [37].
Another very interesting result is the beneficial effect of Ang-(1-7) treatment on the
fibrotic evolution. In the second part of the study (late ARDS study), we tested the
effects of the Ang-(1-7) only at the dose that had produced the better effects in the
acute ARDS study. Two weeks after acid instillation, rats continuously treated with
Ang-(1-7) had a significant reduction in collagen lung deposition (indirectly measured
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Meng et al. [39], that demonstrated protective effects of Ang-(1-7) treatment in murine
LPS- or bleomycin-induced lung injury and lung fibrosis. The inhibitor effect of
Ang-(1-7) on inflammatory cells recruitment seen in the acute phase study may be
related to the reduction of fibrosis in the later phase. We have recently published
[40] about the relationship between the inflammatory response and the fibrotic
evolution, confirming previous data by Jones et al. [41]. Although Ang-(1-7) decreased
pulmonary collagen deposition, it did not attenuate the decrement in respiratory system
compliance in these animals. This might be explained with the fact that lung injury is re-
stricted to a single lobe, and it is not so big to affect the whole respiratory system
compliance.
The limitations of this study should also be acknowledged. First, we did not include a
group of animals treated with blockers of Ang-II receptor (such as Losartan) or,
vice-versa of Ang-II. Indeed, several studies showed beneficial effects of Losartan
treatment in terms of attenuation of lung injury in the ARDS model [33,38,42-44].
Second, we did not demonstrate that the effects of Ang-(1-7) are mediated by Mas
receptor, since we did not consider a group of animals treated with Mas receptor
antagonist (A779). Ang-(1-7) mediates its lung effects through its own receptor and
A779 exacerbates lung injury and collagen deposition [24,40,41].
Conclusions
In this study, angiotensin-(1-7) improved pulmonary function in terms of oxygenation
and inflammatory cells recruitment in a two-hit model of ARDS, characterized by acid
instillation and prolonged injurious ventilation. Ang-(1-7) was effective even when
administration was delayed, emphasizing its true therapeutic potential. The more inter-
esting finding, from a potential clinical perspective, is the persistence of an improved
oxygenation and a reduced lung fibrosis, evaluated in the experimental model of acid
aspiration alone. These results make Ang-(1-7) an exciting plausible therapy for ARDS
and call for further research in this field.
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